A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC
Phase of Trial: Phase I/II
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Neratinib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2018 Planned End Date changed from 1 Jan 2027 to 1 Jan 2026.
- 31 Aug 2018 Biomarkers information updated
- 29 Jan 2018 Planned End Date changed from 1 Apr 2027 to 1 Jan 2027.